$PPCBSep 22, 2026, 8:30 AM ETAI processed
PPCB: PRP shows >90% tumor inhibition and >2.5x survival in preclinical PDAC; pitched as complement to ERAS-0015
AI Summary
Propanc (PPCB) issued a comparative analysis highlighting preclinical PRP results in advanced PDAC models showing >90% mean tumor-growth inhibition, marked metastasis/fibrosis reduction, and >2.5× median overall survival versus controls. The company positions PRP — an IV proenzyme combo that reverses EMT, depletes cancer stem cells and remodels the tumor microenvironment — as a genotype-agnostic, potentially complementary approach to RAS-targeting agents like Erasca’s ERAS-0015 (reported Phase 1 uORRs ~40–57% and FDA Fast Track); Propanc plans a Phase 1b first-in-human study (~40–50 pts) with first dosing targeted for Feb 2027.
Positives
- >90% mean tumor-growth inhibition and >2.5× median overall survival in orthotopic/PDX PDAC preclinical models
- PRP’s mechanism (EMT reversal, CSC depletion, TME remodeling) is genotype-agnostic and positioned as complementary to RAS inhibitors
- FDA Orphan Drug Designation for pancreatic cancer and Phase 1b FIH planned (~40–50 patients, dosing targeted Feb 2027)
Negatives
- Efficacy data is preclinical only; no controlled clinical efficacy data yet
- Comparative claims are cross-modality, non-head-to-head contrasts versus clinical RAS agents
- Prior human experience limited to compassionate-use signals without robust clinical trial evidence